Parishin A-loaded Mesoporous Silica Nanoparticles Modulate Macrophage Polarization to Attenuate Tendinopathy

Lisha Zhu^{1,2,5,6}, Yu Wang^{1,5,6}, Shanshan Jin^{1,5,6}, Yuting Niu^{3,4,5}, Min Yu^{4,5}, Zixin Li^{1,5}, Liyuan Chen^{1,5}, Xiaolan Wu^{1,5}, Chengye Ding^{1,5}, Tianhao Wu^{1,5}, Xinmeng Shi^{1,5}, Yixin Zhang^{1,5}, Dan Luo^{2*}, Yan Liu^{1,5*}

¹Laboratory of Biomimetic Nanomaterials, Department of Orthodontics, Peking University School and Hospital of Stomatology, Beijing 100081, China

²Beijing Institute of Nanoenergy and Nanosystems, Chinese Academy of Sciences, Beijing 101400, China

³Central Laboratory, Peking University School and Hospital of Stomatology, Beijing 100081, China

⁴Department of Prosthodontics, Peking University School and Hospital of Stomatology Beijing 100081, China

⁵National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology & Research Center of Engineering and Technology for Computerized Dentistry Ministry of Health & NMPA Key Laboratory for Dental Materials, Beijing 100081, China

⁶These authors contributed equally: Lisha Zhu, Yu Wang, Shanshan Jin.

*Corresponding author. Email: luodan@binn.cas.cn (D.L.) orthoyan@bjmu.edu.cn (Y.L.)

Table of contents

Supplementary Figure 1. Chemical structure and effective concentrations of PA.

Supplementary Figure 2. Semi-quantification of Western blots in Figure 1b.

Supplementary Figure 3. The regulatory role of PA on human THP-1 derived macrophage polarization and the mechanisms.

Supplementary Figure 4. PA alleviates excessive inflammatory response in the early stage of tendon healing.

Supplementary Figure 5. PA prevents tendon heterotopic ossification.

Supplementary Figure 6. Sustained-release performance and *in vitro* cytotoxicity of MSN.

Supplementary Figure 7. The biological safety of MSN@PA.

Supplementary Figure 8. Original scans of the blots in Fig. 1b, 1e, 3k, 3l.

Supplementary Figure 9. Original scans of the blots in Supplementary Fig. 1b, 3b, 3d.

Supplementary Table 1. Modified Movin score of tendons from the PBS and PA groups.

Supplementary Table 2. Modified Movin score of tendons from the MSN, PA and MSN@PA groups.

Supplementary Table 3. List of reagents or resources used in the study.

Supplementary Table 4. List of rat primers used in the study.

Supplementary Table 5. List of human primers used in the study.

Supplementary Table 6. List of primary and secondary antibodies used in the study.

Supplementary Table 7. Software.



Supplementary Figure 1. Chemical structure and effective concentrations of PA. a Fourier translation infrared spectroscopy (FTIR) spectra of PA. b Western blotting of iNOS and ARG-1 in and PA-treated human THP-1 cells at the concentration of 0, 10 μ M, 20 μ M, 50 μ M and 100 μ M. Scale bar, 200 μ m. c Live/Dead staining of BMDMs treated with dose-dependent PA for 48 h. d Semi-quantification of (c).



Supplementary Figure 2. Semi-quantification of Western blots in Figure 1b. Data

are presented as mean \pm SD. * p < 0.05, n =3.



Supplementary Figure 3. The regulatory role of PA on human THP-1 derived macrophage polarization and the mechanisms. a RT-PCR of *IL-6*, *IL-1* β , *TNF-* α and *ARG-1* expression in DMSO- and PA-treated human THP-1 cells under LPS stimulation. b Western blotting of iNOS, IL-6, and ARG-1 in DMSO- and PA-treated THP-1 cells under LPS stimulation. c Co-immunofluorescence staining of iNOS/CD68 and CD206/CD68 in unstimulated THP-1 cells and DMSO, PA-treated THP-1 cells under LPS stimulation. Scale bar, 50 µm. d Western blotting of total JAK1, phosphorylation of STAT1 and total STAT1 in DMSO- and PA-treated THP-1 cells under LPS stimulation. e Immunofluorescence staining of p-STAT1 in DMSO- and PA-treated THP-1 cells under LPS stimulation. Scale bar, 100 µm. Data are presented as mean ± SD. ** *p* < 0.01 and **** *p* < 0.0001, *n* =3.



Supplementary Figure 4. PA alleviates excessive inflammatory response in the early stage of tendon healing. a Gross view of tendon on 1 week of post-injection. **b** HE and Masson's trichrome stainings of neo-tendons from PBS and PA groups at 1 week. Scale bar, 100 μm.



Supplementary Figure 5. PA prevents tendon heterotopic ossification. a HE and Masson's trichrome stainings of region of heterotopic ossification from PBS and PA groups at 5 weeks. Scale bar, 100 μ m. b Semi-quantification of Western blots in Figure 3k. Data are presented as mean \pm SD. * p < 0.05 and ** p < 0.01, *n* =3.



Supplementary Figure 6. Sustained-release performance and *in vitro* cytotoxicity

of MSN. a Cumulative release concentration curve of PA from MSNs in PBS solution. b Live/Dead staining of BMDMs treated with dose-dependent the MSNs for 24 h. Scale bar, 200 μm.



Supplementary Figure 7. The biological safety of MSN@PA. HE staining results of representative tissue sections of rats (heart, liver, lung, and kidney) after injection of MSN, PA and MSN@PA. Scale bar, 100 μm.



Supplementary Figure 8. Original scans of the blots in Fig. 1b, 1e, 3k, 3l.



Supplementary Figure 9. Original scans of the blots in Supplementary Fig. 1b, 3b, 3d.

| Variable | PBS group | PA group |
|------------------------------------|-------------------|------------------------|
| | (<i>n</i> = 6) | (<i>n</i> = 6) |
| Fiber structure | 2.667 ± 0.516 | $1.500 \pm 0.547 **$ |
| Fiber arrangement | 2.883 ± 0.408 | $1.667 \pm 0.516^{**}$ |
| Rounding of nuclei | 2.500 ± 0.547 | $1.333 \pm 0.516^{**}$ |
| Regional variations of cellularity | 2.667 ± 0.516 | 1.667 ± 0.816 |
| Increase in vascularity | 2.500 ± 0.547 | $1.667 \pm 0.516^{**}$ |
| Decreased collagen stainability | 2.667 ± 0.516 | $1.167 \pm 0.408 **$ |

Supplementary Table 1. Modified Movin score of tendons from the PBS and PA groups.

Note: Values are Mean \pm SD; **: P < 0.01 versus PBS group.

| Variable | MSN group | PA group | MSN@PA group |
|------------------------------------|-------------------|---------------------|----------------------|
| | (n=6) | (<i>n</i> = 6) | (<i>n</i> = 6) |
| Fiber structure | 2.883 ± 0.408 | 1.667 ± 0.516** | 1.333 ± 0.516*** |
| Fiber arrangement | 2.883 ± 0.408 | 2.000 ± 0.633 | $1.500 \pm 0.837 **$ |
| Rounding of nuclei | 2.667 ± 0.516 | 1.667 ± 0.816 | $1.500 \pm 0.837*$ |
| Regional variations of cellularity | 2.500 ± 0.837 | 1.667 ± 0.816 | $1.000 \pm 0.633*$ |
| Increase in vascularity | 2.500 ± 0.837 | 1.833 ± 0.753 | $1.333 \pm 0.516*$ |
| Decreased collagen stainability | 2.667 ± 0.516 | $1.500 \pm 0.548 *$ | $1.500 \pm 0.837*$ |

Supplementary Table 2. Modified Movin score of tendons from the MSN, PA and MSN@PA groups.

Note: Values are Mean \pm SD; *: p < 0.05 versus MSN group, **: P < 0.01 versus MSN group, ***: p < 0.001 versus MSN group.

| Supplementary Table 3. | List of reagents | or resources use | ed in the study. |
|------------------------|------------------|------------------|------------------|
|------------------------|------------------|------------------|------------------|

| REAGENT OR RESOURCE | SOURCE | IDENTIFIER | |
|---|--------------------------|-------------|--|
| Lymphoprep | STEMCELL Technologies | 07811 | |
| Recombinant Rat M-CSF | Peprotech | 400-28 | |
| Lipopolysaccharides | Sigma-Aldrich | L2880 | |
| Recombinant mouse GDF-5 | R&D system | 853-G5 | |
| RPMI 1640 medium | Solarbio | 31800 | |
| Prishin A | Tsbiochem | 62499-28-9 | |
| Dimethyl sulfoxide | Solarbio | D8371 | |
| Phorbol 12-myristate 13-acetate | Sigma-Aldrich | 16561-29-8 | |
| Phosphate buffered solution | Solarbio | P1020 | |
| Live/dead staining kit | Solarbio | CA1630 | |
| Sodium pyruvate | Hyclone | SH30239.01 | |
| Insulin-Transferrin-Selenium | Thermo Fisher Scientific | 41400045 | |
| L-ascorbic acid 2-phosphate | Sigma-Aldrich | A5960 | |
| TGF-β | Peprotech | | |
| Alcian Blue Stain Kit | Solarbio | G1563 | |
| Picro Sirius Red Stain Kit | Abcam | AB150681 | |
| Masson's Trichrome Stain Kit | Solarbio | G1340 | |
| Alizarin Red S solution | Solarbio | G1450 | |
| Safranine O-Fast Green FCF Cartilage Stain Kit | Solarbio | G1371 | |
| Mounting Medium with DAPI | ZSGB-BIO | ZLI-9557 | |
| Dexamethasone | Sigma-Aldrich | D8893 | |
| Dialysis bag | Solarbio | YA1077 | |
| DMEM | Hyclone | SH30021.01B | |
| Fetal bovine serum (FBS) | Thermo Fisher Scientific | 10099-141 | |
| SYBR Green Supermix | Thermo Fisher Scientific | 4385612 | |
| Prime Script RT Reagent Kit | Takara | RR037B | |
| Trizol Reagent | Thermo Fisher Scientific | 15596026 | |
| Trypsin-EDTA | Hyclone | SH30042.01 | |

| b-Glycerophosphate | APEXBIO | 13408-09-8 |
|---|--------------------------|-------------|
| L-Ascorbic acid | Sigma-Aldrich | A5960 |
| Penicillin/streptomycin | Thermo Fisher Scientific | 15070063 |
| Collagenase Type I | Thermo Fisher Scientific | 17100017 |
| Dispase | Roche | 10269638001 |
| RIPA Buffer | Thermo Fisher Scientific | 89900 |
| Protease/Phosphatase Inhibitor Cocktail | Thermo Fisher Scientific | 87786 |
| Pierce BCA protein assay kit | Thermo Fisher Scientific | 23225 |
| L-Glutamine (200mM) | Thermo Fisher Scientific | 25030081 |
| DAB peroxidase substrate kit | ZSGB-BIO | ZLI-9017 |

| TARGET | FOR QPCR DETECTION | | |
|------------|--------------------|-----------------------------|--|
| Cd206 | FORWARD | GACAGACGGACGAGGAGTTCATTATAC | |
| | REVERSE | CCACCAATCACAACAACAACAGTCAAC | |
| Cd163 | FORWARD | TTAGAATCACAGCATGGCACAGGTC | |
| | REVERSE | CCACAAGAGGAAGGCAATGAGAAGG | |
| Argl | FORWARD | AGAGGAGGTGACTCGTACTGTGAAC | |
| | REVERSE | TCTGGCTTATGATTACCTTCCCGTTTC | |
| <i>Il6</i> | FORWARD | AGTTGCCTTCTTGGGACTGATGTTG | |
| | REVERSE | GGTATCCTCTGTGAAGTCTCCTCTCC | |
| Inos | FORWARD | TCTTGGAGCGAGTTGTGGATTGTTC | |
| | REVERSE | AGTGATGTCCAGGAAGTAGGTGAGG | |
| Π1β | FORWARD | AATCTCACAGCAGCATCTCGACAAG | |
| | REVERSE | TCCACGGGCAAGACATAGGTAGC | |
| 1110 | FORWARD | GGCAGTGGAGCAGGTGAAGAATG | |
| | REVERSE | TGTCACGTAGGCTTCTATGCAGTTG | |
| Stat1 | FORWARD | TCGCACCTTCGTCCTCTTCCAG | |
| | REVERSE | TTCACCAACAGTCTCAGCTTCACAG | |
| β-actin | FORWARD | ATCGTGGGCCGCCCTAGGCA | |
| | REVERSE | TGGCCTTAGGGTTCAGAGGGG | |

Supplementary Table 4. List of rat primers used in the study.

| TARGET | FOR QPCR DETECTION | |
|--------|--------------------|--------------------------|
| ARG-1 | FORWARD | TGGACAGACTAGGAATTGGCA |
| | REVERSE | CCAGTCCGTCAACATCAAAACT |
| IL-6 | FORWARD | TACCCCCAGGAGAAGATTCCA |
| | REVERSE | CCGTCGAGGATGTACCGAATT |
| IL-1β | FORWARD | ACCTATCTTCTTCGACACATGGG |
| | REVERSE | GAGGTGGAGAGCTTTCAGTTCAT |
| TNF-α | FORWARD | CTGGTATGGACCCATCTATCTGG |
| | REVERSE | CAGGGCAAATGATCCCAAAGTAGA |
| GAPDH | FORWARD | ATGGGGAAGGTGAAGGTCG |
| | REVERSE | GGGGTCATTGATGGCAACAATA |

Supplementary Table 5. List of human primers used in the study.

Supplementary Table 6. List of primary and secondary antibodies used in the study.

| REAGENT OR RESOURCE | SOURCE | IDENTIFIER | USES |
|--|------------------------------|-------------------------------|--|
| Antibodies | | | |
| Rabbit-polyclonal anti-iNOS | Proteintech | 18985-1-AP | WB (1:1000), IF of tissue (1:100), |
| | | | |
| | D (1 | 10704 1 40 | $\frac{\text{IF of cell (1:300)}}{\text{WD (1.1000) IF } 60^{2}} (1.1000)$ |
| Rabbit-polycional anti-CD206 | Proteintech | 18/04-1-AP | w B (1:1000), IF of ussue (1:100), |
| | | | IF of cell (1:300) |
| Mouse-monoclonal anti-IL-6 | Abcam | AB9324 | WB (1:1000), IHC (1:200) |
| Rabbit-monoclonal anti-Arg-1 | Cell Signaling Technology | #93668 | WB (1:1000), IF of tissue (1:100) |
| Mouse-monoclonal anti-CD68 | Bio-Red | MCA341B | IF of tissue (1:100), |
| | | | |
| | | | IF of cell (1:300) |
| Rabbit-monoclonal anti-JAK1 | Cell Signaling | #50996 | WB (1:1000) |
| | Technology | | |
| Rabbit-monoclonal anti-Phospho- | Cell Signaling | #8826 | WB (1:1000), IF of tissue (1:100), |
| STAT1 | Technology | | |
| | | | IF of cell (1:300) |
| Rabbit- monoclonal anti-STAT1 | Cell Signaling | #14994 | WB (1:1000) |
| | Technology | | |
| Rabbit- polyclonal anti-Col II | Proteintech | 28459-1-AP | IF of tissue (1:100) |
| D 11'4 1 1 1 4' A | D (1 | 12000 1 40 | $IE_{1}(1,100)$ |
| Rabbit- polycional anti-Aggrecan | Abase | 13880-1-AP | IF of tissue (1:100) |
| Rabbit-nolvelonal anti- | Proteintech | <u>AD106950</u> 13281_1_ΛΡ | IF of tissue (1:100) IF of tissue (1:100) |
| Fibromodulin | Tioteinteen | 15201-1-/M | 11 01 (1350c (1.100) |
| Rabbit- polyclonal anti-Osteocalcin | Proteintech | 23418-1-AP | WB (1:1000) |
| Rabbit-Polyclonal anti-Osterix | Invitrogen | PA5-40509 | WB (1:1000) |
| Rabbit- monoclonal anti-Phospho- mTOR | Cell Signaling Technology | #5536 | WB (1:1000), IF of tissue (1:100) |
| Rabbit-monoclonal anti-mTOR | Cell Signaling | #2983 | WB (1:1000) |
| | Technology | | |
| Rabbit-polyclonal anti- | Abcam | AB203676 | IF (1:100) |
| Mouse-monoclonal anti-TNF-q | Abcam | AB1793 | IHC (1·100) |
| Mouse anti-ACTIN | ZSGB-BIO | TA-09 | WB (1:3000) |
| Rabbit-polyclonal anti-Beta | Proteintech | 10068-1-AP | WB (1:3000) |
| TUBULIN | | | · · · · · |
| Mouse-monoclonal anti- VINCULIN | Proteintech | 66305-1-lg | WB (1:3000) |
| Rabbit-monoclonal anti-GAPDH | Cell Signaling | #5174 | WB (1:3000) |
| | Technology | | · · · · |
| HRP-linked anti-mouse IgG | ZSGB-BIO | ZB-2301 | WB (1:5000) |
| HRP-linked anti-rabbit IgG | ZSGB-BIO | ZB-2305 | WB (1:5000) |
| FITC-labeled goat | ZSGB-BIO | ZF-0312 | IF (1:300) |
| anti-mouse IgG (H + L) | 75CD DIO | 7E 0211 | IE (1.200) |
| FIIC-labeled goal anti-rabbit $I_{0}G(H+I)$ | Z20B-BIO | ZF-0311 | IF (1:300) |
| Rhodamine labeled goat anti- | ZSGB-BIO | ZF-0313 | IF (1:300) |
| mouse IgG $(H + L)$ | | | |
| Rhodamine labeled goat | ZSGB-BIO | ZF-0316 | IF (1:300) |
| anti-rabbit 1gG (H + L) | 7SGB_PIO | PV0001 | ШС |
| anti-rabbit IgG | 250D-DIO | 1 1 9001 | inc |
| Horseradish enzyme labelled goat | ZSGB-BIO | PV9002 | IHC |
| anti-mouse IgG | | | |

IF: Immunofluorescence; WB: Western blotting; IHC: Immunohistochemistry

Supplementary Table 7. Software.

| Software | |
|----------------------------------|---|
| ChemDraw 20.0 | https://www.chemdraw.com. |
| Image J (v1.53k) | https://imagej.nih.gov |
| Graph Pad Prism 9.00 | https://www.graphpad.com |
| Micro-CT Evaluation CTAnsoftware | http://www.blue-scientific.com/bruker-micro-ct- |
| (version 1.15) | |
| | software |
| | |
| NRecon | http://www.blue-scientific.com/bruker-micro-ct- |
| | software |
| CTvox | http://www.blue-scientific.com/bruker-micro-ct- |
| | software |
| OMNI Specta | https://www.thermofisher.cn |
| LAS X 3.0 | https://www.leica-microsystems.com.cn |
| Origin2021 | https://www.originlab.com/ |
| NIS-Elements | https://www.nis-elements.com |
| ZEN 2.3 | https://www.zeiss.com.cn |